Kerri Glassner

1.3k total citations · 1 hit paper
35 papers, 916 citations indexed

About

Kerri Glassner is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Kerri Glassner has authored 35 papers receiving a total of 916 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Genetics, 22 papers in Epidemiology and 15 papers in Surgery. Recurrent topics in Kerri Glassner's work include Inflammatory Bowel Disease (23 papers), Microscopic Colitis (15 papers) and Eosinophilic Esophagitis (8 papers). Kerri Glassner is often cited by papers focused on Inflammatory Bowel Disease (23 papers), Microscopic Colitis (15 papers) and Eosinophilic Esophagitis (8 papers). Kerri Glassner collaborates with scholars based in United States. Kerri Glassner's co-authors include Bincy Abraham, Eamonn M.M. Quigley, Hoda M. Malaty, Khurram Nasir, Nehal N. Mehta, Caroline Perry, Tanushree Agrawal, Amit K. Dey, Isaac Acquah and Miguel Cainzos‐Achirica and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and Journal of the American College of Cardiology.

In The Last Decade

Kerri Glassner

30 papers receiving 904 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The microbiome and inflammatory bowel disease

2020 603 citations Kerri Glassner, Bincy Abraham et al. Journal of Allergy and Clinical Immunology profile →

Peers

Kerri Glassner

GENET

MB

EPIDE

SURGE

ID

Guilherme Piovezani Ramos United States

Timothy L. Zisman United States

Lani Prideaux Australia

Rupert Pullan United Kingdom

Tomoki Aomatsu Japan

Tomohisa Sujino Japan

D. Valpiani Italy

L. Kupčinskas Lithuania

Frederico R. C. Costa Brazil

Ray Boyapati Australia

Guilherme Piovezani Ramos United States

Kerri Glassner

500 ×1.1

GENET

411 ×1.0

MB

326 ×1.0

EPIDE

299 ×1.6

SURGE

64 ×0.5

ID

Citations per year, relative to Kerri Glassner Kerri Glassner (= 1×) peers Guilherme Piovezani Ramos

Countries citing papers authored by Kerri Glassner

Since Specialization

Citations

This map shows the geographic impact of Kerri Glassner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kerri Glassner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kerri Glassner more than expected).

Fields of papers citing papers by Kerri Glassner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kerri Glassner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kerri Glassner. The network helps show where Kerri Glassner may publish in the future.

Co-authorship network of co-authors of Kerri Glassner

This figure shows the co-authorship network connecting the top 25 collaborators of Kerri Glassner. A scholar is included among the top collaborators of Kerri Glassner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kerri Glassner. Kerri Glassner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Irani, Mohamad, et al.. (2025). A Guide to De-escalation of Combination Therapy in Inflammatory Bowel Disease: A Retrospective Cohort Study. Crohn s & Colitis 360. 7(2). otaf026–otaf026.

2.

Glassner, Kerri, et al.. (2024). Therapeutic Potential of Etrasimod in the Management of Moderately-to-Severely Active Ulcerative Colitis: Evidence to Date. Clinical and Experimental Gastroenterology. Volume 17. 337–345. 5 indexed citations

3.

Glassner, Kerri, et al.. (2024). Therapeutic drug monitoring in patients with inflammatory bowel disease on ustekinumab. Journal of Digestive Diseases. 25(4). 214–221. 1 indexed citations

4.

Glassner, Kerri, et al.. (2024). Therapeutic drug monitoring in inflammatory bowel disease patients on vedolizumab. Journal of Digestive Diseases. 25(2). 91–99. 2 indexed citations

5.

Abraham, Bincy, et al.. (2024). S3976 A Case of an Uncomplicated Pregnancy on Dual Biologic Therapy With Ustekinumab and Vedolizumab for Crohn’s Disease. The American Journal of Gastroenterology. 119(10S). S2581–S2582.

6.

Abraham, Bincy, et al.. (2024). Postoperative Ustekinumab Drug Levels and Disease Activity in Patients with Crohn’s Disease. Digestive Diseases and Sciences. 69(8). 2944–2954. 1 indexed citations

7.

Fan, Christopher, et al.. (2023). Clinical Evaluation of Upadacitinib in the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (UC): Patient Selection and Reported Outcomes. Clinical and Experimental Gastroenterology. Volume 16. 21–28. 6 indexed citations

8.

Glassner, Kerri, et al.. (2023). VEDOLIZUMAB, USTEKINUMAB AND TOFACITINIB AS TRIPLE THERAPY FOR ULCERATIVE COLITIS. Inflammatory Bowel Diseases. 29(Supplement_1). S81–S82.

9.

Ergun, Gulchin A., et al.. (2023). Patient Attitudes and Barriers to Endoscopy During the COVID-19 Pandemic. Digestive Diseases and Sciences. 68(6). 2303–2314. 1 indexed citations

10.

Warren, Benjamin, et al.. (2023). Development of Shingles on Tofacitinib Despite Completion of Recombinant Varicella-Zoster Virus Vaccine Series. ACG Case Reports Journal. 10(12). e01221–e01221. 1 indexed citations

11.

Alayo, Quazim A., Osama Altayar, Kerri Glassner, et al.. (2022). Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease. Crohn s & Colitis 360. 4(1). otac002–otac002. 57 indexed citations

12.

Divatia, Mukul, et al.. (2022). S2091 Sevelamer-Induced Colitis. The American Journal of Gastroenterology. 117(10S). e1425–e1425.

13.

Nasir, Khurram, Isaac Acquah, Amit K. Dey, et al.. (2022). Inflammatory bowel disease and atherosclerotic cardiovascular disease in U.S. adults—A population-level analysis in the national health interview survey. SHILAP Revista de lepidopterología. 9. 100316–100316. 17 indexed citations

14.

Agrawal, Tanushree, Isaac Acquah, Amit K. Dey, et al.. (2021). Prevalence of cardiovascular risk factors in a nationally representative adult population with inflammatory bowel disease without atherosclerotic cardiovascular disease. SHILAP Revista de lepidopterología. 6. 100171–100171. 16 indexed citations

15.

Glassner, Kerri, Bincy Abraham, & Eamonn M.M. Quigley. (2020). The microbiome and inflammatory bowel disease. Journal of Allergy and Clinical Immunology. 145(1). 16–27. 603 indexed citations breakdown →

16.

Cainzos‐Achirica, Miguel, Kerri Glassner, Amit K. Dey, et al.. (2020). Inflammatory Bowel Disease and Atherosclerotic Cardiovascular Disease. Journal of the American College of Cardiology. 76(24). 2895–2905. 69 indexed citations

17.

Glassner, Kerri & Bincy Abraham. (2019). The use of vedolizumab in pregnancy and breastfeeding in women with inflammatory bowel disease. 43(9). 13–18. 1 indexed citations

18.

Glassner, Kerri, et al.. (2019). 2063 A Stellar Case of Stelara in the Treatment of Lymphocytic Colitis. The American Journal of Gastroenterology. 114(1). S1154–S1154. 3 indexed citations

19.

Glassner, Kerri, et al.. (2018). Autoimmune liver disease and the enteric microbiome. AIMS Microbiology. 4(2). 334–346. 3 indexed citations

20.

Glassner, Kerri, Hoda M. Malaty, & Bincy Abraham. (2017). Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease Among Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 23(6). 998–1003. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact